Cantor Fitzgerald Estimates CG Oncology FY2025 Earnings

CG Oncology, Inc. (NASDAQ:CGON) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of CG Oncology in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will earn ($1.52) per share for the year. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share.

A number of other brokerages have also recently issued reports on CGON. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of CG Oncology in a report on Friday, January 10th. TD Cowen started coverage on CG Oncology in a research note on Tuesday, January 7th. They issued a “buy” rating on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $66.00 price objective on shares of CG Oncology in a research report on Friday, December 6th. Bank of America reissued a “buy” rating and set a $65.00 target price on shares of CG Oncology in a report on Tuesday, October 8th. Finally, UBS Group began coverage on CG Oncology in a report on Thursday, October 24th. They set a “buy” rating and a $60.00 price target for the company. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $63.88.

CG Oncology Trading Up 0.1 %

Shares of CG Oncology stock opened at $30.79 on Thursday. The business’s 50 day moving average is $30.92 and its 200-day moving average is $34.10. CG Oncology has a 12-month low of $25.77 and a 12-month high of $50.23.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.30 million.

Insider Buying and Selling at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $34.54, for a total value of $34,540.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Hong Fang Song sold 700,000 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $28.00, for a total transaction of $19,600,000.00. Following the transaction, the director now owns 3,003,931 shares in the company, valued at approximately $84,110,068. The trade was a 18.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 702,000 shares of company stock valued at $19,664,200 in the last ninety days.

Institutional Investors Weigh In On CG Oncology

Several institutional investors have recently made changes to their positions in the stock. Amalgamated Bank raised its holdings in CG Oncology by 107.6% in the 3rd quarter. Amalgamated Bank now owns 1,621 shares of the company’s stock valued at $61,000 after acquiring an additional 840 shares in the last quarter. M&T Bank Corp increased its position in shares of CG Oncology by 55.7% in the third quarter. M&T Bank Corp now owns 16,758 shares of the company’s stock worth $632,000 after purchasing an additional 5,996 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CG Oncology in the third quarter valued at about $241,000. Profund Advisors LLC bought a new stake in CG Oncology during the second quarter worth about $300,000. Finally, JPMorgan Chase & Co. grew its stake in CG Oncology by 59.1% during the third quarter. JPMorgan Chase & Co. now owns 31,071 shares of the company’s stock worth $1,172,000 after buying an additional 11,542 shares in the last quarter. 26.56% of the stock is currently owned by institutional investors.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.